Stoke Therapeutics, Inc. (STOK)
After hours:
| Previous Close | 11.94 |
| Open | 11.72 |
| Bid | 11.57 x 100 |
| Ask | 11.65 x 100 |
| Day's Range | 11.38 - 12.12 |
| 52 Week Range | 3.35 - 16.40 |
| Volume | |
| Avg. Volume | 1,319,868 |
| Market Cap | 604.591M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass., May 06, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause
- Business Wire
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BEDFORD, Mass., April 29, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his p
- Business Wire
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BEDFORD, Mass., April 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership te
